Novamind expands its treatment footprint via a new partnership with Uruguay-based Bienstar Wellness.
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways provides further details on its Phase IIb results for the treatment of Treatment Resistant Depression, including reporting of additional "patient improvements".
TSI EDITOR |
2021-12-01
Albert Labs (CSE: ABRT) Receive Conditional Approval for CSE Listing & Appoint Chrystal Capital Partners to Advise on European Listing
UK-based Albert Labs receives conditional approval from the Canadian Securities Exchange (CSE) to commence trading under the symbol "ABRT". Trading expected to commence in early 2022.
TSI EDITOR |
2021-11-30
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
Cybin seeks FDA approval for a new Phase 2 clinical trial aimed at treating "distress" among frontline healthcare practitioners.
TSI EDITOR |
2021-11-30
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
atai Life Sciences adds to its holding in Compass Pathways, raising its ownership interest back to 20.8%.
TSI EDITOR |
2021-11-29
Red Light Holland Reports Second Quarter 2021 Results
Red Light Holland reports its results for Q2 fiscal 2021. - Quarterly revenues up to CAD$485,738 - A 64% increase in gross profit - 56% increase in the number of retail outlets selling TRIP products
TSI EDITOR |
2021-11-29
Novamind Reports Fiscal Q1 Financial Results and Operating Highlights
Novamind reports revenues of CAD$1.86 million for Q1 fiscal 2022, a 113% year-over-year increase. The company has total working capital of CAD$6.8 million
TSI EDITOR |
2021-11-29
Novamind Unveils New Logo and Invests in Unified Brand
Novamind announces unified branding of all subsidiaries and brands, and includes a new corporate logo.
TSI EDITOR |
2021-11-24
Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note
Seelos Therapeutics announces $20 million in new funding via convertible note, with an option for an additional $30 million.
TSI EDITOR |
2021-11-24
COMPASS Pathways granted fifth US patent for crystalline psilocybin
The 5th USPTO patent for Compass Pathways covers methods of treating depression with crystalline psilocybin.
TSI EDITOR |
2021-11-23
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now